Skip to main content
Full access
Communications and Updates
Published Online: 1 January 2012

Differential Lithium Efficacy in Reducing Suicidal Behaviors Compared With Suicidal Thoughts

To the Editor: We applaud the extensive effort and recognize the ethically challenging nature of designing and conducting the randomized clinical trial comparing lithium and valproate in the treatment of suicidal behavior (1) reported in the October 2011 issue of the Journal. Such studies are desperately needed to identify pharmacological treatment approaches that reduce suicide. The report by Oquendo et al. (1) should further encourage such experimental approaches. However, our concern is that the article's conclusions could discourage clinicians from prescribing lithium for at-risk bipolar patients.
Lithium therapy has been associated with a reduction in the risk of suicidal behavior, defined as a suicide attempt or completion (2). However, there exists limited evidence to suggest that planning for a suicide, a subtype of suicidal ideation, is attenuated by lithium therapy. In a recent consensus statement, experts argued that combining suicidal thinking and behavior should not be a standard endpoint for randomized controlled trials (3), and ideation per se does not have a well-documented biological basis. Oquendo et al. emphasize that they calculated power to detect a relative risk of 5 or greater, which compares favorably with the relative risks associated previously with not taking lithium versus taking lithium (relative risk=4.91, 95% CI=3.82–6.31) (2). However, sufficient power is only derived from including individuals with a plan for a suicidal act. Can the authors provide a power analysis only for suicidal behavior as an outcome, and discuss conclusions based on the outcome of that analysis?
A current hypothesis about the biological mechanism of lithium action in preventing suicide—consistent with available evidence—is that lithium does not reduce suicidal thoughts, but it reduces acting on such thoughts by decreasing impulsivity, aggression, or decision-making deficits, which are well-defined endophenotypes intermediate to suicidal behaviors (4). It is possible that lithium could have the greatest effect in preventing suicidal acts in patients who have a plan for suicide and that by intervening, as per the experimental design, the therapeutic effects of lithium would not be observed. We recognize that the experimental options were limited by ethical concerns that the authors were unmistakably correct to follow, but that does not reduce the rationale for considering that such a mechanism may be important.

Footnote

Accepted for publication in October 2011.

References

1.
Oquendo MA, Galfalvy HC, Currier D, Grunebaum MF, Sher L, Sullivan GM, Burke AK, Harkavy-Friedman J, Sublette ME, Parsey RV, Mann JJ: Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry 2011; 168:1050–1056
2.
Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J: Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8:625–639
3.
Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, Mann JJ, Alphs LD, Broich K, Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan ND, Sheehan DV: Suicidality and risk of suicide: definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry 2010; 71:e1–e21
4.
Kovacsics CE, Gottesman II, Gould TD: Lithium's antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 2009; 49:175–198

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 98 - 99
PubMed: 22223017

History

Accepted: October 2011
Published online: 1 January 2012
Published in print: January 2012

Authors

Affiliations

Todd D. Gould, M.D.
Adem Can, Ph.D.
Irving I. Gottesman, Ph.D., Hon. F.R.C.Psych.
Philippe Courtet, M.D., Ph.D.

Funding Information

The authors report no financial relationships with competing interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share